Welcome to our dedicated page for Neurosense Therapeutics news (Ticker: NRSN), a resource for investors and traders seeking the latest updates and insights on Neurosense Therapeutics stock.
NeuroSense Therapeutics Ltd. develops therapies for severe neurodegenerative diseases, led by PrimeC, a proprietary fixed-dose oral extended-release combination of ciprofloxacin and celecoxib. Company news centers on PrimeC clinical and biomarker data in amyotrophic lateral sclerosis, Alzheimer’s disease program updates, regulatory interactions, and scientific publications or conference presentations related to the PARADIGM and PARAGON programs.
Recurring developments also include intellectual-property coverage for the PrimeC composition, including patent grants in Brazil, the United States and Australia, as well as Nasdaq listing compliance notices, shareholder voting matters, capital-structure disclosures, governance updates, material agreements, and operating or financial results.
NeuroSense Therapeutics (Nasdaq: NRSN) announced the granting of a key patent in Australia for its lead ALS treatment, PrimeC, which combines ciprofloxacin and celecoxib. This patent complements the prior US patent and is valid until June 2038. The CEO highlighted the importance of this patent in enhancing their commercialization strategy. NeuroSense plans to start a Phase 2b study in May 2022 and has received Orphan Drug Designation in the US and Europe. Patent applications are also pending in various regions including Japan and Canada.
NeuroSense Therapeutics (Nasdaq: NRSN) announced that Dr. Shiran Zimri will present at the ASENT 2022 Annual Meeting on March 3, 2022, discussing PrimeC, a novel ALS therapy. PrimeC combines two FDA-approved drugs to target ALS, which currently has limited treatment options. The Phase 2a trial showed significant clinical improvements, and a Phase 2b study is planned for H1 2022. CEO Alon Ben-Noon emphasizes the importance of Dr. Zimri's presentation to ALS experts, aiming to establish PrimeC as a viable treatment.
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) announced a presentation at the Aegis Capital Virtual Conference on February 25, 2022 at 8:30AM EST, part of a three-day event from February 23-25.
The conference will feature a company overview, and the slide deck will be available on their website. NeuroSense is focused on advanced therapies for neurodegenerative diseases like ALS and plans to start a Phase 2b study for its drug PrimeC in early 2022.
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) will present at the BIO CEO & Investor Conference on February 15, 2022, at 9:30 AM Eastern. The conference takes place from February 14 to 17 at the Marriott Marquis, New York City. CEO Alon Ben-Noon will discuss recent achievements and future plans, with the presentation available on NeuroSense's website. The clinical-stage biotechnology company focuses on treatments for neurodegenerative diseases like ALS and aims to begin Phase 2b trials for its drug PrimeC in mid-2022.
NeuroSense Therapeutics (NRSN) has initiated the third stage of a biomarker study with Massachusetts General Hospital (MGH) to investigate ALS biomarkers related to its lead product candidate, PrimeC. Building on previous studies, this new phase aims to evaluate biomarkers in patients not previously treated with PrimeC, providing further insight into ALS symptom progression. The collaboration is expected to enhance understanding of PrimeC's mechanism of action, support clinical trial optimization, and expedite potential commercialization.
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) announced that its Phase IIa clinical trial results will be presented at the 16th International Conference on Alzheimer's & Parkinson's Diseases in March 2022. In Q4 2021, the company also shared data at three notable conferences, highlighting positive outcomes from its Phase IIa study and promising changes in ALS-related biomarkers. CEO Alon Ben-Noon emphasized the strong reception from the scientific community and the company's solid financial position following its IPO, enabling progress in its ALS clinical program.
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has expanded its board of directors with four new members following its recent IPO. The new directors possess significant experience in healthcare and biotechnology, which will aid in the development of NeuroSense's product portfolio. Notably, Dr. Ferenc Tracik has been appointed as Chief Medical Officer, bringing expertise in neurodegenerative therapies. CEO Alon Ben-Noon emphasized the importance of these appointments in advancing the company's objectives to deliver innovative treatments for ALS and other neurodegenerative diseases.
NeuroSense Therapeutics (NRSN) has successfully closed its initial public offering (IPO) on the Nasdaq Capital Market, raising approximately $12 million in gross proceeds from 2,000,000 units sold at $6.00 each. The offering includes warrants for an additional 300,000 shares, with net proceeds expected to be around $9.9 million. Funds will be utilized to advance the clinical development of its lead candidate, PrimeC, for ALS and support research for Alzheimer's and Parkinson's. The IPO marks a significant milestone for the company, focusing on developing treatments for neurodegenerative diseases.